XTL Biopharmaceuticals Ltd (XTLB) — Cash Flow-to-Debt Ratio
XTL Biopharmaceuticals Ltd (XTLB) has a Cash Flow-to-Debt Ratio of -0.10x as of December 2017, meaning its operating cash flow of ILA-301.00K could theoretically repay 0% of its total liabilities (ILA2.97 Million) in one year. See working capital to net assets of XTL Biopharmaceuticals Ltd to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
XTL Biopharmaceuticals Ltd Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for XTL Biopharmaceuticals Ltd across 12 annual periods. Also explore XTLB net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for XTL Biopharmaceuticals Ltd (2013–2024)
Year-by-year debt coverage analysis for XTL Biopharmaceuticals Ltd. For market capitalisation and broader financial context, see XTL Biopharmaceuticals Ltd (XTLB) total market value.
| Year | CF-to-Debt Ratio | Operating CF (ILA) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.52x | ILA-1.62 Million | ILA3.12 Million | ▲ +84.9% |
| 2023 | -3.43x | ILA-707.00K | ILA206.00K | ▲ +28.8% |
| 2022 | -4.82x | ILA-901.00K | ILA187.00K | ▼ -490.2% |
| 2021 | -0.82x | ILA-1.05 Million | ILA1.28 Million | ▲ +75.6% |
| 2020 | -3.35x | ILA-850.00K | ILA254.00K | ▲ +14.5% |
| 2019 | -3.91x | ILA-908.00K | ILA232.00K | ▼ -21.3% |
| 2018 | -3.23x | ILA-816.00K | ILA253.00K | ▼ -750.6% |
| 2017 | -0.38x | ILA-1.12 Million | ILA2.97 Million | ▲ +92.8% |
| 2016 | -5.25x | ILA-1.73 Million | ILA330.00K | ▼ -23.0% |
| 2015 | -4.27x | ILA-1.86 Million | ILA436.00K | ▼ -66.8% |
| 2014 | -2.56x | ILA-2.47 Million | ILA965.00K | ▼ -26.0% |
| 2013 | -2.03x | ILA-2.50 Million | ILA1.23 Million | — |